The association of the hepatitis B virus infection and diffuse large B-cell lymphoma

Guodong Yu; Jijing Han; Jianmei Xu

doi:10.15537/smj.2024.45.5.20231024

References

1.↵
1. Wang H,
2. Men P,
3. Xiao Y,
4. Gao P,
5. Lv M,
6. Yuan Q, et al.
Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis 2019; 19: 811.
OpenUrl PubMed
2.
1. Yang S,
2. Ding C,
3. Cui Y,
4. Wu J,
5. Yu C,
6. Chen P, et al.
Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open 2017; 7: e014947.
OpenUrl Abstract/FREE Full Text
3.↵
1. Liu J,
2. Zhang S,
3. Wang Q,
4. Shen H,
5. Zhang M,
6. Zhang Y, et al.
Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis 2016; 16: 80–86.
OpenUrl CrossRef PubMed
4.↵
1. Visentini M,
2. Pica A,
3. D’Ippolito G,
4. Sculco E,
5. La Gualana F,
6. Gragnani L, et al.
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy. Ann Hematol 2023; 102: 3457–3463.
OpenUrl
5.↵
1. Elbedewy TA,
2. Elashtokhy HE,
3. Rabee ES,
4. Kheder GE.
Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening. J Egypt Nat Can Inst 2015; 27: 11–18.
OpenUrl
6.↵
1. Zhan Z,
2. Guo W,
3. Wan X,
4. Wang B,
5. Li J,
6. Wang H, et al.
Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP. Front Immunol 2024; 15: 1324113.
OpenUrl
7.↵
1. Kang X,
2. Ba L,
3. Han C,
4. Qi X.
Clinical analysis and prognostic significance of hepatitis B virus infections with diffuse large B-cell lymphoma. Cancer Manag Res 2020; 12: 2839–2851.
OpenUrl
8.↵
1. Lemaitre M,
2. Brice P,
3. Frigeni M,
4. Hermine O,
5. Arcaini L,
6. Thieblemont C, et al.
Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. J Infection 2020; 80: 219–224.
OpenUrl
9.↵
1. Liu Y,
2. Barta SK.
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019; 94: 604–616.
OpenUrl CrossRef PubMed
10.↵
1. Park SY,
2. Kim SI,
3. Kim H,
4. Lee Y,
5. Park SH.
An autopsy case of Epstein–Barr virus associated diffuse large B-cell lymphoma of the central nervous system in an immunocompromised host. J Pathol Transl Med 2017; 52: 51–55.
OpenUrl
11.↵
1. Chen MH,
2. Hsiao LT,
3. Chiou TJ,
4. Liu JH,
5. Gau JP,
6. Teng HW, et al.
High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol 2008; 87: 475–480.
OpenUrl CrossRef PubMed Web of Science
12.↵
1. Su TH,
2. Liu CJ,
3. Tseng TC,
4. Chou SW,
5. Liu CH,
6. Yang HC, et al.
Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin’s lymphoma and multiple myeloma. Aliment Pharm Therap 2019; 49: 589–598.
OpenUrl
13.↵
1. Cao X,
2. Wang Y,
3. Li P,
4. Huang W,
5. Lu X,
6. Lu H.
HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021; 11: 685706.
OpenUrl
14.↵
1. Sinha M,
2. Sundar K,
3. Premalata CS,
4. Asati V,
5. Murali A,
6. Bajpai AK, et al.
Pro-oncogenic, intra host viral quasispecies in diffuse large B cell lymphoma patients with occult hepatitis B virus infection. Sci Rep 2019; 9: 14516.
OpenUrl
15.↵
1. Zinzani PL.
The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 426–432.
OpenUrl Abstract/FREE Full Text
16.↵
1. Zhang M,
2. Gao F,
3. Peng L,
4. Shen L,
5. Zhao P,
6. Ni B, et al.
Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis. Cancer Cell Int 2021; 21: 524.
OpenUrl
17.↵
1. Nuersulitan R,
2. Li M,
3. Mi L,
4. Wu M,
5. Ji X,
6. Liu Y, et al.
Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era. Front Oncol 2022; 12: 989258.
OpenUrl
18.↵
1. Yu S,
2. Luo H,
3. Pan M,
4. Luis AP,
5. Xiong Z,
6. Shuai P, et al.
Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016; 38: 1035–1043.
OpenUrl
19.
1. Negara I,
2. Buruiana S,
3. Tomacinschii V,
4. Dudnic C.
Hepatitis B and C infections among lymphoma patients: a national study in the Republic of Moldova. J Infect Dev Ctries 2022; 16: 1897–1905.
OpenUrl
20.↵
1. Liang JH,
2. Gao R,
3. Dai JC,
4. Gale RP,
5. Li W,
6. Fan L, et al.
The prognostic role of HBV infection in chronic lymphocytic leukemia. J Cancer Res Clin 2018; 144: 1309–1315.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] 1.↵
Wang H,
Men P,
Xiao Y,
Gao P,
Lv M,
Yuan Q, et al.
Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis 2019; 19: 811.
OpenUrl PubMed

[2] Wang H,

[3] Men P,

[4] Xiao Y,

[5] Gao P,

[6] Lv M,

[7] Yuan Q, et al.

[8] 2.
Yang S,
Ding C,
Cui Y,
Wu J,
Yu C,
Chen P, et al.
Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open 2017; 7: e014947.
OpenUrl Abstract/FREE Full Text

[9] Yang S,

[10] Ding C,

[11] Cui Y,

[12] Wu J,

[13] Yu C,

[14] Chen P, et al.

[15] 3.↵
Liu J,
Zhang S,
Wang Q,
Shen H,
Zhang M,
Zhang Y, et al.
Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis 2016; 16: 80–86.
OpenUrl CrossRef PubMed

[16] Liu J,

[17] Zhang S,

[18] Wang Q,

[19] Shen H,

[20] Zhang M,

[21] Zhang Y, et al.

[22] 4.↵
Visentini M,
Pica A,
D’Ippolito G,
Sculco E,
La Gualana F,
Gragnani L, et al.
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy. Ann Hematol 2023; 102: 3457–3463.
OpenUrl

[23] Visentini M,

[24] Pica A,

[25] D’Ippolito G,

[26] Sculco E,

[27] La Gualana F,

[28] Gragnani L, et al.

[29] 5.↵
Elbedewy TA,
Elashtokhy HE,
Rabee ES,
Kheder GE.
Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening. J Egypt Nat Can Inst 2015; 27: 11–18.
OpenUrl

[30] Elbedewy TA,

[31] Elashtokhy HE,

[32] Rabee ES,

[33] Kheder GE.

[34] 6.↵
Zhan Z,
Guo W,
Wan X,
Wang B,
Li J,
Wang H, et al.
Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP. Front Immunol 2024; 15: 1324113.
OpenUrl

[35] Zhan Z,

[36] Guo W,

[37] Wan X,

[38] Wang B,

[39] Li J,

[40] Wang H, et al.

[41] 7.↵
Kang X,
Ba L,
Han C,
Qi X.
Clinical analysis and prognostic significance of hepatitis B virus infections with diffuse large B-cell lymphoma. Cancer Manag Res 2020; 12: 2839–2851.
OpenUrl

[42] Kang X,

[43] Ba L,

[44] Han C,

[45] Qi X.

[46] 8.↵
Lemaitre M,
Brice P,
Frigeni M,
Hermine O,
Arcaini L,
Thieblemont C, et al.
Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. J Infection 2020; 80: 219–224.
OpenUrl

[47] Lemaitre M,

[48] Brice P,

[49] Frigeni M,

[50] Hermine O,

[51] Arcaini L,

[52] Thieblemont C, et al.

[53] 9.↵
Liu Y,
Barta SK.
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019; 94: 604–616.
OpenUrl CrossRef PubMed

[54] Liu Y,

[55] Barta SK.

[56] 10.↵
Park SY,
Kim SI,
Kim H,
Lee Y,
Park SH.
An autopsy case of Epstein–Barr virus associated diffuse large B-cell lymphoma of the central nervous system in an immunocompromised host. J Pathol Transl Med 2017; 52: 51–55.
OpenUrl

[57] Park SY,

[58] Kim SI,

[59] Kim H,

[60] Lee Y,

[61] Park SH.

[62] 11.↵
Chen MH,
Hsiao LT,
Chiou TJ,
Liu JH,
Gau JP,
Teng HW, et al.
High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Ann Hematol 2008; 87: 475–480.
OpenUrl CrossRef PubMed Web of Science

[63] Chen MH,

[64] Hsiao LT,

[65] Chiou TJ,

[66] Liu JH,

[67] Gau JP,

[68] Teng HW, et al.

[69] 12.↵
Su TH,
Liu CJ,
Tseng TC,
Chou SW,
Liu CH,
Yang HC, et al.
Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin’s lymphoma and multiple myeloma. Aliment Pharm Therap 2019; 49: 589–598.
OpenUrl

[70] Su TH,

[71] Liu CJ,

[72] Tseng TC,

[73] Chou SW,

[74] Liu CH,

[75] Yang HC, et al.

[76] 13.↵
Cao X,
Wang Y,
Li P,
Huang W,
Lu X,
Lu H.
HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021; 11: 685706.
OpenUrl

[77] Cao X,

[78] Wang Y,

[79] Li P,

[80] Huang W,

[81] Lu X,

[82] Lu H.

[83] 14.↵
Sinha M,
Sundar K,
Premalata CS,
Asati V,
Murali A,
Bajpai AK, et al.
Pro-oncogenic, intra host viral quasispecies in diffuse large B cell lymphoma patients with occult hepatitis B virus infection. Sci Rep 2019; 9: 14516.
OpenUrl

[84] Sinha M,

[85] Sundar K,

[86] Premalata CS,

[87] Asati V,

[88] Murali A,

[89] Bajpai AK, et al.

[90] 15.↵
Zinzani PL.
The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 426–432.
OpenUrl Abstract/FREE Full Text

[91] Zinzani PL.

[92] 16.↵
Zhang M,
Gao F,
Peng L,
Shen L,
Zhao P,
Ni B, et al.
Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis. Cancer Cell Int 2021; 21: 524.
OpenUrl

[93] Zhang M,

[94] Gao F,

[95] Peng L,

[96] Shen L,

[97] Zhao P,

[98] Ni B, et al.

[99] 17.↵
Nuersulitan R,
Li M,
Mi L,
Wu M,
Ji X,
Liu Y, et al.
Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era. Front Oncol 2022; 12: 989258.
OpenUrl

[100] Nuersulitan R,

[101] Li M,

[102] Mi L,

[103] Wu M,

[104] Ji X,

[105] Liu Y, et al.

[106] 18.↵
Yu S,
Luo H,
Pan M,
Luis AP,
Xiong Z,
Shuai P, et al.
Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016; 38: 1035–1043.
OpenUrl

[107] Yu S,

[108] Luo H,

[109] Pan M,

[110] Luis AP,

[111] Xiong Z,

[112] Shuai P, et al.

[113] 19.
Negara I,
Buruiana S,
Tomacinschii V,
Dudnic C.
Hepatitis B and C infections among lymphoma patients: a national study in the Republic of Moldova. J Infect Dev Ctries 2022; 16: 1897–1905.
OpenUrl

[114] Negara I,

[115] Buruiana S,

[116] Tomacinschii V,

[117] Dudnic C.

[118] 20.↵
Liang JH,
Gao R,
Dai JC,
Gale RP,
Li W,
Fan L, et al.
The prognostic role of HBV infection in chronic lymphocytic leukemia. J Cancer Res Clin 2018; 144: 1309–1315.
OpenUrl

[119] Liang JH,

[120] Gao R,

[121] Dai JC,

[122] Gale RP,

[123] Li W,

[124] Fan L, et al.

Main menu

User menu

Search

The association of the hepatitis B virus infection and diffuse large B-cell lymphoma

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

The association of the hepatitis B virus infection and diffuse large B-cell lymphoma

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS